KRYS Krystal Biotech, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$339.06

Period return

+49.93 (+17.27%)

Volume

442.9K

2026-07-21O $336.72 H $341.96 L $325 C $339.06MA5 $345.03MA20 $360.01MA60 $321.51MA120 $293.15

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 03.Highin 13 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 22.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 18.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 05.LowBUY3 months ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.
2026. 05. 05.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 27.MediumHOLD4 months ago
Wolfe Research: Peer Perform
US analyst rating / recommendation change.
2026. 02. 25.LowBUY5 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 02. 19.LowBUY5 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 02. 18.LowBUY5 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $322.78 · 9 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
HQ: Pittsburgh, PA, United States
Fiscal year end: —
Employees: 295

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 03.	After market close (AMC)	$1.94	—	—	$125.25M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$1.2	—	—	$88.18M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$1.47	—	—	$199.38M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.56	—	—	$115.54M	Reported

Krystal Biotech, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 22.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 18.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 06.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 05. 05.	Evercore ISI Group	—	Maintain	Outperform → Outperform	—	Evercore ISI Group: Outperform
2026. 05. 05.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 27.	Wolfe Research	—	Initiate coverage	— → Peer Perform	—	Wolfe Research: Peer Perform